Lerociclib
- Generic Name
- Lerociclib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34N8O
- CAS Number
- 1628256-23-4
- Unique Ingredient Identifier
- WBH8AY6ENB
- Background
Lerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- EQRx International, Inc.
- Registration Number
- NCT05712941
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath